Skip to main content
Clinical Trials/NCT05671744
NCT05671744RecruitingNot Applicable

Validation of a Cell-Based Technology for Non-Invasive-Prenatal-Diagnosis (CB-NIPD) Using Circulating Whole Fetal Cells From Maternal Peripheral Blood.

Menarini Biomarkers Singapore1 site in 1 country1,500 target enrollmentStarted: November 22, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
1,500
Locations
1
Primary Endpoint
Fetal chromosomal abnormalities detection in circulating fetal cells,

Study Overview

Brief Summary

The aim of this clinical study is the evaluation of clinical performance of a cell-based non-invasive test technology for fetal aneuploidies and segmental imbalances detection in a high-risk pregnancies population.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Screening
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Participant has a viable singleton or twin pregnancy
  • Women who have already been selected by their treating physician to undergo an invasive fetal diagnostic procedure
  • Participant is at least 18 years old and can provide informed consent

Exclusion Criteria

  • Unable to provide informed consent
  • Prenatal diagnosis of clinical Chorioamnionitis
  • Intake of drugs or exposure to teratogenic agents
  • Infections that carry a risk of vertical transmission
  • Known maternal viral diseases: HIV and HCV, HBV

Outcomes

Primary Outcomes

Fetal chromosomal abnormalities detection in circulating fetal cells,

Time Frame: 2 year

Evaluation of clinical performance of a cell-based technology for fetal chromosomal abnormalities detection in circulating fetal cells, using maternal blood samples from a population of high-risk pregnancies undergoing clinically indicated fetal diagnostic procedures.

Secondary Outcomes

  • Number of suitable fetal cells(2 year)
  • Fetal sex assessment(2 year)

Investigators

Sponsor
Menarini Biomarkers Singapore
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials